A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 250-256

  Ohyama, Sumika ^a   Takano, Hiroki ^a   Iino, Tomoharu ^a   Nishimura, Teruyuki ^a   Zhou, Yun Ping ^b   Langdon, Ronald B ^b   Zhang, Bei B ^b   Eiki, Jun Ichi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Glimepiride; Glucokinase activator; Insulin secretion; Islet of Langerhans; Secondary failure; Sulfonylurea

Indexed keywords

3 (2 HYDROXY 1 METHYLETHOXY) 5 [4 (METHYLSULFONYL) PHENOXY] N 1,3 THIAZOL 2 YLBENZAMIDE; ENZYME ACTIVATOR; GLIMEPIRIDE; GLIPIZIDE; GLUCOKINASE; GLUCOSE; INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; CH3OCF2CH(CF3)OCH2F; ETHER DERIVATIVE; FLUORINATED HYDROCARBON; GLUCOSE BLOOD LEVEL; SULFONYLUREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; THERAPY EFFECT; TREATMENT DURATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; ENZYME ACTIVATION; METABOLISM; TIME;

ANIMALS; BLOOD GLUCOSE; DRUG INTERACTIONS; ENZYME ACTIVATION; ETHERS; GLUCOKINASE; HYDROCARBONS, FLUORINATED; INSULIN; MALE; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 77953807137     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.054     Document Type: Article

References (37)

1. Alemzadeh R., Fledelius C., Bodvarsdottir T., Sturis J. Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism 2004, 53:441-447.
2. Anello M., Gilon P., Henquin J.C. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. Br. J. Pharmacol. 1999, 127:1883-1891.
3. Asakawa T., Moritoh Y., Kataoka O., Suzuki N., Takeuchi K., Odaka H. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009, 85:122-126.
4. Ashcroft F.M., Gribble F.M. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999, 42:903-919.
5. Ball A.J., Flatt P.R., McClenaghan N.H. Acute and long-term effects of nateglinide on insulin secretory pathways. Br. J. Pharmacol. 2004, 142:367-373.
6. Ball A.J., Flatt P.R., McClenaghan N.H. Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide. Biochem. Pharmacol. 2005, 69:59-63.
7. Cook M.N., Girman C.J., Stein P.P., Alexander C.M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. 2007, 24:350-358.
8. Dunbar J.C., Foà P.P. An inhibitory effect of tolbutamide and glibenclamide (glyburide) on the pancreatic islets of normal animals. Diabetologia 1974, 10:27-35.
9. Filipponi P., Marcelli M., Nicoletti I., Pacifici R., Santeusanio F., Brunetti P. Suppressive effect of long term sulfonylurea treatment on A, B, and D cells of normal rat pancreas. Endocrinology 1983, 113:1972-1979.
10. Greenwood R.H., Mahler R.F., Hales C.N. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976, 307:444-447.
11. Grimsby J., Sarabu R., Corbett W.L., Haynes N.E., Bizzarro F.T., Coffey J.W., Guertin K.R., Hilliard D.W., Kester R.F., Mahaney P.E., Marcus L., Qi L., Spence C.L., Tengi J., Magnuson M.A., Chu C.A., Dvorozniak M.T., Matschinsky F.M., Grippo J.F. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003, 301:370-373.
12. Grimsby J., Berthel S.J., Sarabu R. Glucokinase activators for the potential treatment of type 2 diabetes. Curr. Top. Med. Chem. 2008, 8:1524-1532.
13. Hosokawa Y.A., Leahy J.L. Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes 1997, 46:808-813.
14. Iino T., Hashimoto N., Sasaki K., Ohyama S., Yoshimoto R., Hosaka H., Hasegawa T., Chiba M., Nagata Y., Eiki J., Nishimura T. Structure-activity relationships of 3, 5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg. Med. Chem. 2009, 17:3800-3809.
15. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., Viberti G., Study Group A.D.O.P.T. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006, 355:2427-2443.
16. Kamata K., Mitsuya M., Nishimura T., Eiki J., Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004, 12:429-438.
17. Kang L., Dunn-Meynell A.A., Routh V.H., Gaspers L.D., Nagata Y., Nishimura T., Eiki J., Zhang B.B., Levin B.E. Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing. Diabetes 2006, 55:412-420.
18. Karam J.H., Sanz N., Salamon E., Nolte M.S. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986, 35:1314-1320.
19. Kawaki J., Nagashima K., Tanaka J., Miki T., Miyazaki M., Gonoi T., Mitsuhashi N., Nakajima N., Iwanaga T., Yano H., Seino S. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 1999, 48:2001-2006.
20. Lindblad U., Lindwall K., Sjöstrand A., Ranstam J., Melander A. Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes. Obes. Metab. 2001, 3:443-451.
21. Matschinsky F.M. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 2009, 8:399-416.
22. Matschinsky F.M., Magnuson M.A., Zelent D., Jetton T.L., Doliba N., Han Y., Taub R., Grimsby J. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006, 55:1-12.
23. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., Turner R.C. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 1998, 15:297-303. UKPDS 26.
24. McClenaghan N.H., Ball A.J., Flatt P.R. Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure. Biochem. Pharmacol. 2001, 61:527-536.
25. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004, 53(Suppl 3):S151-155.
26. Nakamura A., Terauchi Y., Ohyama S., Kubota J., Shimazaki H., Nambu T., Takamoto I., Kubota N., Eiki J., Yoshioka N., Kadowaki T., Koike T. Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. Endocrinology 2009, 150:1147-1154.
27. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
28. Pontiroli A.E., Calderara A., Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab. Rev. 1994, 10:31-43.
29. Riedel A.A., Heien H., Wogen J., Plauschinat C.A. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007, 27:1102-1110.
30. Remedi M.S., Nichols C.G. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med. 2008, 5:e206.
31. Rustenbeck I. Desensitization of insulin secretion. Biochem. Pharmacol. 2002, 63:1921-1935.
32. Rustenbeck I., Wienbergen A., Bleck C., Jörns A. Desensitization of insulin secretion by depolarizing insulin secretagogues. Diabetes 2004, 53(Suppl 3):S140-150.
33. Someya Y., Nakano R., Tahara A., Takasu T., Takeuchi A., Nagase I., Matsuyama-Yokono A., Hayakawa M., Sasamata M., Miyata K., Uchiyama Y. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure. Eur. J. Pharmacol. 2009, 622:71-77.
34. Takahashi A., Nagashima K., Hamasaki A., Kuwamura N., Kawasaki Y., Ikeda H., Yamada Y., Inagaki N., Seino Y. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res. Clin. Pract. 2007, 77:343-350.
35. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012. UK Prospective Diabetes Study (UKPDS) Group.
36. Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Kawakubo M., Buchanan T.A. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517-522.
37. Wåhlin-Boll E., Sartor G., Melander A., Scherstén B. Impaired effect of sulfonylurea following increased dosage. Eur. J. Clin. Pharmacol. 1982, 22:21-25.